COVID-19: Pfizer, AstraZeneca vaccines shots reduce hospitalisations, virus spread: Report

*Study results reveal Oxford-AstraZeneca vaccine cut hospital admissions by 94 percent by fourth week after a single dose, while Pfizer/BioNTech led to 85 percent reduction in hospitalisations in Scotland

*Pfizer requests the US FDA for permission to keep its vaccine at a higher, easier-to-manage temperature

Alexander Davis | ConsumerConnect

Latest findings in Scotland have revealed that vaccination reduced the risk of hospitalisations from COVID-19 by over 80 percent, enhancing the growing signs of effectiveness of immunisation since the exercise began late last year.

It was gathered the shot developed by AstraZeneca Plc and University of Oxford cut hospital admissions by 94 percent by the fourth week after a single dose, with the one from Pfizer Inc. and BioNTech SE also leading to an 85 percent reduction in hospitalisations, according to study results published Monday, February 22, 2021.

The data add to a growing body of evidence that inoculations are having a significant effect in countries with the most advanced campaigns.

The Pfizer vaccine as well appeared to stop the vast majority of recipients in Israel from becoming infected, according to a draft publication confirmed by a person familiar with the vaccination work, Bloomberg report said.

Researchers in Scotland compared outcomes for patients who had received a first shot with results for those who had not.

Among those ages 80 and over, one of the highest-risk groups, vaccination was associated with an 81 percent reduction in hospitalisation across both vaccines.

The results should further ease concerns about the United Kingdom’s (UK) decision to delay second doses of the two-shot Pfizer and AstraZeneca vaccines in an effort at speedin up protection for more of the population, according to report.

Some 17.5 million people have had a first dose, about a third of all adults in the UK.

Hitherto, the country was reported to have had Europe’s highest death toll from the Coronavirus, at more than 120,000, but hospitalisations have fallen by more than half from a January peak.

Likewise, report indicates the Pfizer/BioNTech SE COVID-19 vaccine also appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunisation will curb transmission of the fatal Coronavirus.

The vaccine, which is being rolled out in the country in a national immunisation programme that began December 20, 2020, was 89.4 percent effective at preventing laboratory-confirmed infections, according to a draft publication posted on Twitter and confirmed by a sourced connected with the work.

It was learnt the companies worked with Israel’s Health Ministry on the preliminary observational analysis, which wasn’t peer-reviewed, though some scientists disputed its accuracy.

The results, also reported in Der Spiegel, are the latest in a series of positive data to emerge out of Israel, which has given more COVID vaccines per capita than anywhere else in the world.

Almost half of the population has had at least one dose of vaccine. Separately, Israeli authorities Saturday, February 20 confirmed the Pfizer-BioNTech shot was 99 percent effective at preventing deaths from the virus.

Further still, if confirmed, the early results on lab-tested infections are encouraging because they indicate the vaccine may also prevent asymptomatic carriers from spreading the virus that causes COVID-19, report stated.

That’s not been clear because the clinical trials that tested the safety and efficacy of vaccines focused on the ability to stop symptomatic infections.

Meanwhile, the need to keep the Pfizer vaccine at extremely low temperatures has presented logistical issues that have complicated the vaccine’s rollout in certain countries.

Now, Pfizer is asking the US Food and Drug Administration (FDA) for permission to keep the vaccine at a higher, easier-to-manage temperature, according to report.

The drug company has submitted supporting data to the FDA, including stability data generated on batches manufactured over the past nine months of COVID-19 vaccine development.

The current standard for storage is between minus 112 and minus 76 degrees Fahrenheit.

However, Pfizer says the vaccine is stable between minus 13 and 5 degrees Fahrenheit.

Albert Bourla, Pfizer’s Chief Executive Officer (CEO), said:  “We have been continuously performing stability studies to support the production of the vaccine at commercial scale, with the goal of making the vaccine as accessible as possible for healthcare providers and people across the US and around the world.”

Kindly Share This Story